Cristal Therapeutics develops nanomedicines that entrap existing and new drugs in proprietary CriPec® polymer nanoparticles to improve distribution, selective release and tolerability. Its lead candidate, CriPec® docetaxel, has shown enhanced efficacy and safety in preclinical studies and completed a clinical phase Ia trial assessing tolerability and pharmacokinetics. The company is advancing CriPec® docetaxel through a planned clinical phase Ib to confirm recommended phase II dosing and expects to start a larger phase II later in the year. Cristal is also developing CriPec® DUO (dual-drug nanoparticles) and CriPec® oligonucleotide delivery programs to broaden therapeutic applications. The company is privately held and based in Maastricht; a recent €12.8 million financing will support the upcoming clinical trials and intensified platform and preclinical development. Cristal has an existing partnership with iTeos Therapeutics to combine CriPec® nanoparticles with immuno-oncology small-molecule modulators. Cristal Therapeutics develops nanomedicines using its patented CriPec® technology to entrap drugs in polymer nanoparticles (0.0001 mm diameter) to improve distribution and enable more selective drug release. The company’s lead program is CriPec® docetaxel, intended to provide more effective chemotherapy with fewer side effects. Preclinical studies since 2011 have demonstrated safety and efficacy for various CriPec®-based candidates in animal models. Cristal plans to begin the first clinical study of CriPec® docetaxel in early 2015. The company completed a financing round of over €6 million to support that clinical start. Leadership changes accompanied the financing: co‑founder Joost Holthuis was appointed CEO effective 1 December 2014, and founder Cristianne Rijcken moved to Chief Scientific Officer.

Total raised

$21M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2017